SRC and prostate carcinoma: Therefore, inhibition of Src kinase is now considered as a promising therapeutic target of prostate cancer, and dasatinib, the dual Src and Bcr-Abl tyrosine kinase inhibitor, is now under evaluation of for the treatment of CRPC and metastatic prostate cancer [53].